Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04968847 · ClinicalTrials.gov registry record · NA
FemaSeed LOCAL Artificial Insemination Trial
A NA study, sponsored by Femasys.
- Completed
- Registry status
- NA
- Development phase
- 314
- Enrollment target
NCT04968847 is a NA study that has completed, run by Femasys. The registered enrollment target is 314 participants.
The verdict
NCT04968847, a NA study, has completed, sponsored by Femasys.
- COMPLETED
- Registry status
- NA
- Development phase
- 314 participants
- Enrollment target
Study Summary
Brief Summary: The objectives of the trial are to evaluate the safety and effectiveness of the FemaSeed Localized Directional Insemination for artificial insemination, now known as the FemaSeed Intratubal Insemination since FDA Cleared under K231730 in September 2023.
Interventions
- DEVICE FemaSeed Localized Directional Insemination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 314 participants |
| Start Date | 2021-07-15 |
| Est. Completion | 2024-04-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04968847
The ClinicalTrials.gov registry entry for NCT04968847 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 314 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Femasys, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FemaSeed Localized Directional Insemination is the first listed.
NCT04968847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04968847 about?
NCT04968847 is a clinical study titled "FemaSeed LOCAL Artificial Insemination Trial". Brief Summary: The objectives of the trial are to evaluate the safety and effectiveness of the FemaSeed Localized Directional Insemination for artificial insemination, now known as the FemaSeed Intratubal Insemination since FDA Cleared under K231730 in September 2023.
What is the current status of trial NCT04968847?
This trial is currently completed. It is a NA study. The enrollment target is 314 participants. The study started on 2021-07-15. Estimated completion is 2024-04-30.
What interventions are being tested in trial NCT04968847?
The interventions under investigation include: FemaSeed Localized Directional Insemination (DEVICE).
Who is sponsoring clinical trial NCT04968847?
This trial is sponsored by Femasys, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.